We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
-5.15%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$325M
AUM Growth
+$325M
Cap. Flow
+$154M
Cap. Flow %
47.4%
Top 10 Hldgs %
48.17%
Holding
91
New
22
Increased
30
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$9.77M
2
VCYT icon
Veracyte
VCYT
+$5.92M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$4.32M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.3M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$3.98M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.72M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.45M
3
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$1.55M
4
IMGN
Immunogen Inc
IMGN
+$993K
5
IMTX icon
Immatics
IMTX
+$714K

Sector Composition

Rank Sector Weight
1 Healthcare 64.89%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
76
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-41,002
Closed -$2.54K
IMUX icon
77
Immunic
IMUX
$175M
– –
-6,848
Closed -$774
ITOS
78
DELISTED
iTeos Therapeutics
ITOS
– –
-138,843
Closed -$4.47K
CYPH
79
Cypherpunk Technologies Inc
CYPH
$63M
– –
-103,216
Closed -$1.81K
NBIX icon
80
Neurocrine Biosciences
NBIX
$18.2B
– –
-20,482
Closed -$1.92K
NXTC icon
81
NextCure
NXTC
$21.8M
– –
-16,349
Closed -$953
VRDN icon
82
Viridian Therapeutics
VRDN
$2.13B
– –
-126,136
Closed -$2.33K
ASLN
83
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-12,500
Closed -$1.59K
IMGN
84
CALL
DELISTED
Immunogen Inc
IMGN
– –
-300,000
Closed -$1.43K
PNT
85
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-204,679
Closed -$1.63K
APTX
86
PUT
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-201,600
Closed -$458
JNCE
87
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-248,347
Closed -$1.69K
LHDX
88
DELISTED
Lucira Health, Inc. Common Stock
LHDX
– –
-310,734
Closed -$1.11K
MSAC
89
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
– –
-131,151
Closed -$1.28K
SRRA
90
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-443,381
Closed -$14.2K
CALA
91
DELISTED
Calithera Biosciences, Inc
CALA
– –
-11,090
Closed -$74
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Silverarc Capital Management held 91 positions worth $325M, up 134,306% from $242K the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $154M of net new capital in Q2 2022, opening 22 new positions and adding to 30 existing holdings. Its largest new stake was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.72M trimmed.

  • Silverarc Capital Management's largest Q2 2022 buy was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q2 2022, an estimated $9.77M increase.
  • Silverarc Capital Management's biggest Q2 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $9.72M.
  • Silverarc Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $27K.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $325M portfolio in Q2 2022.
  • Silverarc Capital Management opened 22 new positions and closed 21 in Q2 2022.
  • Silverarc Capital Management's portfolio value rose 134,306% quarter-over-quarter to $325M.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.